ArteraAI: The Biomarker Test Redefining
ฝัง
- เผยแพร่เมื่อ 10 ก.พ. 2025
- Donate to PCRI: pcri.org/donate/
For more information, visit pcri.org
1:34 What is a biomarker test?
3:55 How can patients be sure that it's safe to forego hormone therapy?
7:21 Why do one-third of patients benefit from ADT?
10:04 What markers point toward hormone therapy being necessary?
11:20 What PSA and PSMA results indicate that a patient should try hormone therapy?
12:09 Is age often a factor when deciding to embark on hormone therapy?
13:20 How would a biomarker test help a patient decide on whether to start hormone therapy?
14:26 What were the results of the Phase 3 randomized studies on ArturaAI?
15:33 How should patients decide between IMRT and brachytherapy?
17:23 How does IMRT alone compare to IMRT with hormone therapy?
18:18 How advisable is it for the average patient to get the ArturaAI test?
19:48 Does taking hormone therapy later lessen its effectiveness?
21:29 Alex's conclusions
Don't know your stage? Take the quiz: visit www.prostatecan...
To learn more about prostate cancer, visit www.pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer | New Journal of Medicine Evidence: evidence.nejm.org/doi/full/10.1056/EVIDoa2300023
I'm 66 and had Gleason 9, 19.9 PSA with a 2.8x2.8 cm tumor and opted for surgery on 12-13-2024 by Dr Baig at St Vincent Mercy Hospital in Toledo, Ohio because I wanted to avoid chemical castration. Margins were clear, 4 lymph nodes were clear and 6 week PSA was undetectable. Currently in therapy for incontinence and have begun Trimix penile injections. I am very thankful for PCRI and weighed my options before choosing surgery.
Alex, thank you very much for yet another informative and most helpful presentation.
I personally find all your broadcasts exceptionally helpful and I always share them with friends whom are also diagnosed with Prostate Cancer.
I’m unsure if the doctor is related to you (same surname) but in any case, it’s clear he is top of his game and would wish to thank him also.
It’s a mixed bag over the pond, London seems to be advanced with the majority of procedures, however, the further North has its challenges.
In the final analysis, l have used the logic of your program to allow a balanced approach.
Best regards
Thank you both!
🎯 Key points for quick navigation:
00:00 *📊 Overview of ArteraAI's Role in Prostate Cancer Treatment*
- Introduction of ArteraAI focusing on intermediate risk prostate cancer patients.
- Discussion on the impact of hormone therapy on quality of life.
- Highlighting the importance of AI in analyzing pathology and diagnostic data.
03:00 *⚖️ Hormone Therapy vs. Radiation Therapy*
- Exploration of treatment options: hormone therapy and radiation therapy.
- Explanation of side effects associated with hormone therapy and its necessity based on individual risk assessment.
- Factors influencing the decision to use hormone therapy based on patient age and cancer characteristics.
06:00 *🔎 Evaluating Prostate Cancer Risk with Biomarker Tests*
- Introduction of the AI-based biomarker test aimed at assessing cancer relapse risk.
- Discussion on the results of the test providing probabilities of relapse without hormone therapy.
- Emphasis on the necessity of informed patient decisions regarding treatment based on test outcomes.
12:00 *📈 Review of Clinical Trials and Their Implications*
- Summary of clinical trials involving patients treated with various therapies.
- The significance of distinguishing between favorable and unfavorable cancer profiles in treatment decisions.
- Insights on how brachytherapy compares to IMRT and its potential for improved outcomes without hormone therapy.
18:00 *💡 Practical Application of Test Results in Treatment Choices*
- Discussion on how the test can guide physicians in treatment planning.
- Importance of contextualizing test results within a comprehensive understanding of patient circumstances.
- The notion that not all patients may benefit equally from the test, emphasizing personalized treatment approaches.
20:30 *🌟 Conclusion: Future Directions in Prostate Cancer Management*
- Overview of the general effectiveness of current treatments and patient education on risks.
- Explanation on potential benefits of delaying hormone therapy and managing relapses in prostate cancer.
- Encouragement for patients to engage in discussions about the relevance of tests and treatment options with healthcare providers.
21:25 *🧬 Introduction to Biomarker Testing in Prostate Cancer*
- Biomarker tests provide personalized insights into prostate cancer treatment options.
- The test analyzes pathology and diagnostic reports using an AI model.
- It’s essential to consider multiple factors such as PSA levels, age, Gleason score, and imaging results in decision-making.
- Encourages shared decision-making between patient and doctor for better outcomes.
22:22 *🌐 Understanding Test Availability and Costs*
- Information about the licensing and availability of the biomarker test for patients.
- The test is not currently licensed in California and New York, but may be soon.
- Medicare coverage may be available, and options for out-of-pocket payments exist.
- Encourages patients to stay informed about the test and its potential benefits.
23:04 *⚕️ Hormone Therapy Insights and Management*
- Discusses the importance of managing side effects of hormone therapy.
- Suggestions include lifestyle changes like diet and exercise to lessen side effects.
- Highlights the significance of predictive tests for assessing treatment efficacy while prioritizing quality of life.
Made with HARPA AI
Very helpful information. I am finally beginning to look at the options I have in dealing with my Prostate Cancer comming back after 16 years after a Prostatectomy . Thanks
How old are you now if l may ask.
Good info!
ArteraAI Prostate Test: artera.ai/for-patients
Thank you for information I was 4+3 “unfavorable “ dx in April 2023 Was on ADT for 8 months & had IMRT radiation in 2023 All my blood tests including PSA were normal & stable 1 month ago I didn’t have PMSA test or AI So far I am in remission & will have blood tests in July to keep track Cancer is a difficult to diagnose Thank you & God bless you
Diagnosed PC in December Gleason 9 after mri biopsy with petscan showing just approaching one lymph node as urologist puts it all cars in the city except one on highway and stopped at first petrol station. Referred to Mater hospital ICON Cancer centre and now on hormone blocker Elligard awaiting radiation in mid March for nine weeks- because I’m attending my son’s wedding in NZ later in the month. Over two weeks since hormone therapy started and have not felt any side effects and continue with walking my dogs and eating healthy and everything else in moderation
Very interesting. Where does SBRT fit in this or is it considered an extension of IMRT. I am 73. I had a rising PSA (2.5 to 4.8) a year ago. Gleason 7. We did a PSMA Pet scan. All localized. I did SBRT and am now on Orgovyx. My side effects are sort of OK. I get hot waves but not the high spikes that some get. Blood sugar is up. but Metformin fixes that. Cholesterol is up but Emetimibe. Fairly low energy. I wonder if I should talk to my doctor about ArteraAI? Thanks. Again, very interesting.
Can you talk about the different types of pc? As in the more aggressive ones. Also talk about lung metastasis.
Could you explain the Phoenix Criteria? Is waiting until 2+Nadir still an acceptable treatment plan? Thx!
Does this test correlate with tests like oncotype ? In other words is someone with a high or low oncotype score likely to have a similar ArteraAI score.
Great news
Been there, done that.....
There is FLA and TULSA PRO for low and low-intermediate (3+4) instead of radiation.
It's not for me. I'm 67 gleason 7+, I'm going through Lupron hormone therapy. with Xtandi oral chemo. And as you said it's pretty horrific and my doctor said the stronger chemo data shows a longer life. I have a PSA .02. No one would even know I have metastatic stage 4 cancer. The hot flashes are horrible I wake every few hours roasting when sleeping.
As to AI... It's too early to say how it will help.
One thing needs to be said, health care in the USA is only for those, who can afford to pay 10s of thousands of dollars, everyone else be damned. Your best strategy to survive any type of cancer, is to move to Canada before you get cancer. Oh, the current GOP plan is to reduce coverage of all therapies...by the tune of $2T over the next 10years. In other words.... You are in your own
What it boils down to is cancer can be treated but never cured and doesn't matter what you do. Pick your poision !
The size effects are pitiful and embarrassing if that is all you have to offer after 60 years - - - -this is pitiful !
Though it sucks , we must be thankful that we have it. It's better than nothing right
Is there any way one can be treated at a distance by someone like this? This open minded personalized treatment viewpoint is radically different from the cookie cutter, everybody gets extreme treatment whether they like it or not.That we deal with in Canada.
ArteraAI Insurance Information: artera.ai/billing